Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

US adults are taking more supplements as multivitamins lose ground

16

Jun 2026

US adults are taking more supplements as multivitamins lose ground

A 25-year NHANES analysis of 63,442 US adults found that reported dietary supplement use rose from 51% to 60%, with the largest increases among adults aged 65 years and older. Use shifted away from multivitamin-multimineral products and toward vitamins, minerals, botanicals, and nonvitamin nonmineral supplements marketed for immune, anti-inflammatory, gut, skin, and joint health.

New grant supports research into blinding retinal diseases

16

Jun 2026

New grant supports research into blinding retinal diseases

A University of Minnesota Medical School research team has been awarded a 4-year, $2.2 million grant from the National Eye Institute to better understand the underlying causes of retinal diseases, such as age-related macular degeneration (AMD), and develop new treatments that could benefit patients.

Maternal RSV vaccine shows 68% protection against infant RSV hospitalization

16

Jun 2026

Maternal RSV vaccine shows 68% protection against infant RSV hospitalization

In a test-negative case-control study of 274 hospitalized infants aged 90 days or younger, maternal RSVpreF vaccination was associated with 67.6% effectiveness against RSV-associated acute respiratory illness hospitalization. Protection was similar against RSV-linked lower respiratory tract disease, with the highest point estimate in the first month of life, although confidence intervals were wide.

JMIR articles address AI clinical decision-making and health care worker burnout

16

Jun 2026

JMIR articles address AI clinical decision-making and health care worker burnout

JMIR Publications released two feature stories in its News and Perspectives section. Shalini Kathuria Narang's "Can Humanlike Reasoning Be Replicated in Large Language Models for Clinical Decision-Making?" and Sara Novak's "How Health Care Workers Can Manage Digital Fatigue" offer complementary looks into the capabilities of artificial intelligence in diagnostics, and the real-world exhaustion faced by medical professionals managing digital systems.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.